Oxidative stress in Alzheimer disease

Cell Adhesion and Migration

Volumn 3, Issue 1, 2009, Pages 88-93

  Gella, Alejandro ^a   Durany, Nuria ^a  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Advanced glycation endproducts; Ageing; Alzheimer disease; Amyloid; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMINOGUANIDINE; AMYLOID PROTEIN; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; DNA; FREE RADICAL; GLUCOSE; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOXAMINE; THIOCTIC ACID;

AGING; ALZHEIMER DISEASE; BRAIN TISSUE; CELL DEATH; FEEDBACK SYSTEM; GLUCOSE METABOLISM; HUMAN; LIPID OXIDATION; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

EID: 67049134478     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.3.1.7402     Document Type: Review

References (97)

1. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm 1996; 47:73-101. (Pubitemid 26275591)
2. Gsell W, Strein I, Krause U, Riederer P. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease-a comparative review. J Neural Transm 1997; 51:145-159 (Pubitemid 28055697)
3. Retz W, Gsell W, Münch G, Rosler M, Riederer P. Free radicals in Alzheimer's disease. J Neural Transm 1998; 54:221-236
4. Rösler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm 1998; 54:211-219 (Pubitemid 28539358)
5. Durany N, Munch G, Michel T, Riederer P. Investigations on oxidative stress and therapeutical implications in dementia. Eur Arch Psychiatry Clin Neurosci 1999; 249:68-73. (Pubitemid 30011745)
6. Christen Y. Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000; 71:621-629 (Pubitemid 30061247)
7. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004; 3:205-214
8. Sayre LM, Moreira PI, Smith MA, Perry G. Metal ions and oxidative protein modification in neurological disease. Ann Ist Super Sanita 2005; 41:143-164 (Pubitemid 43169859)
9. Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008; 21:172-188
10. Forster MJ, Dubey A, Dawson KM, Stutts WA, Lal H, Sohal RS. Age-related losses of cognitive function and motor skills in mice are associated with oxidative protein damage in the brain. Proc Natl Acad Sci USA 1996; 93:4765-4769 (Pubitemid 26162825)
11. Schippling S, Kontush A, Arlt S, Buhmann C, Sturenburg HJ, Mann U, et al. Increased lipoprotein oxidation in Alzheimer's disease. Free Radic Biol Med 2000; 28:351-360 (Pubitemid 30110650)
12. Mohsen MMAE, Iravani MM, Spencer JPE, Rose S, Fahim AT, Motawi TMK, et al. Ageassociated changes in protein oxidation and proteasome activities in rat brain: Modulation by anti-oxidants. Biochemical Biophysical Res Commun 2005; 336:386-391 (Pubitemid 41268663)
13. Smith MA, Kutty RK, Rickey PL, Yan SD, Stern D, Chader GJ, et al. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 1994; 145:42-47 (Pubitemid 24217481)
14. Gupta A, Hasan M, Chander R, Kapoor K. Age-related elevation of lipid peroxidation products: diminution of superoxide dismutase activity in the central nervous system of rats. Gerontology 1991; 37:305-309
15. Cini M, Moretti A. Studies on lipid peroxidation and protein oxidation in the aging brain. Neurobiol Aging 1995; 16:53-57
16. Ramassamy C, Krzywkowski P, Averill D, Lussier-Cacan S, Theroux L, Christen Y, et al. Impact of ApoE deficiency on oxidative insults and antioxidant levels in the brain. Brain Res Mol Brain Res 2001; 86:76-83. (Pubitemid 32124761)
17. Picklo MJ, Montine TJ, Amarnath V, Neely MD. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 2002; 184:187-197
18. Bassett CN, Montine TJ. Lipoproteins and lipid peroxidation in Alzheimer's disease. J Nutr Health Aging 2003; 7:24-29
19. Mecocci P, Beal MF, Cecchetti R, Polidori MC, Cherubini A, Chionne F, et al. Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and human brain. Mol Chemi Neuropathol 1997; 31:53-64. (Pubitemid 27328636)
20. Hamilton ML, Van Remmen H, Drake JA, Yang H, Guo ZM, Kewitt K, et al. Does oxidative damage to DNA increase with age? Proc. Natl Acad. Sci USA 2001; 98:10469-10474 (Pubitemid 32803043)
21. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res 2007; 35:7497-7504
22. Perrig WJ, Perrig P, Stahelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc 1997; 45:718-724 (Pubitemid 27248781)
23. Berr C. Cognitive impairment and oxidative stress in the elderly: results of epidemiological studies. Biofactors 2000; 13:205-209 (Pubitemid 32107366)
24. Thornalley PJ. Glutathione-dependent detoxification of alpha-oxoaldehydes by the glyoxalase system-involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem Biol Interactions 1998; 112:137-151 (Pubitemid 28271940)
25. Chen TS, Richie JP, Lang CA. The effect of aging on glutathione and cysteine levels in different regions of the mouse brain. Proc Soc Exp Biol Med 1989; 190:399-402. (Pubitemid 19106950)
26. Iantomasi T, Favilli F, Marraccini P, Stio M, Treves C, Quatrone A, et al. Age and GSH metabolism in rat cerebral cortex, as related to oxidative and energy parameters. Mech Ageing Dev 1993; 70:65-82. (Pubitemid 23241455)
27. Sasaki T, Senda M, Kim S-N, Kojima S, Kubodera A. Age-related changes of glutathione content, glucose transport and metabolism, and mitochondrial electron transfer function in mouse brain. Nucl Med Biol 2001; 28:25-31. (Pubitemid 32155962)
28. Liu RM. Downregulation of g-glutamil cysteine synthetase regulatory subunit gene expression in rat brain tissue during aging. J Neurosci Res 2002; 68:344-351 (Pubitemid 34462540)
29. Sandhu SK, Kaur G. Alterations in oxidative stress scavenger system in aging rat brain and lymphocytes. Biogerontology 2002; 3:161-173 (Pubitemid 34678894)
30. Wang H, Liu H, Liu R. Gender difference in glutathione metabolism during aging in mice. Exp Gerontol 2003; 38:507-517 (Pubitemid 36549037)
31. Calabrese V, Scapagnini G, Ravagna A, Colombrita C, Spadaro F, Butterfield DA, et al. Increased expression of heat shock proteins in rat brain during aging: relationship with mitochondrial function and glutathione redox state. Mech Ageing Dev 2004; 125:325-335 (Pubitemid 38438512)
32. Donahue AN, Aschner M, Lash LH, Syversen T, Sonntag WE. Growth hormone administration to aged animals reduces disulfide glutathione levels in hippocampus. Mech Ageing Dev 2006; 127:57-63. (Pubitemid 41713514)
33. Zhu Y, Carvey PM, Ling Z. Age-related changes in glutathione and glutathione-related enzymes in rat brain. Brain Res 2006; 1090:35-44. (Pubitemid 43817938)
34. Gsell W, Conrad R, Hickethier M, Sofic E, Frölich L, Wichart I, et al. Decreased catalase activity but unchanged superoxide dismutase activity in brains of patients with dementia of Alzheimer type. J Neurochem 1995; 64:1216-1223
35. Davies MJ. The oxidative environment and protein damage. Biochim Biophys Acta 2005; 1703:93-109. (Pubitemid 40170433)
36. Berlett BS, Stadtman ER. Protein oxidation in aging, disease and oxidative stress. J Biol Chem 1997; 272:20313-20316 (Pubitemid 27355575)
37. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A. Protein carbonylation, cellular dysfunction and disease progression. J Cell Mol Med 2006; 10:389-406. (Pubitemid 44870187)
38. Levine RL, Williams JA, Stadtman ER, Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol 1994; 233:346-357 (Pubitemid 24177560)
39. Smith MA, Sayre LM, Anderson VE, Harris PL, Beal MF, Kowall N, et al. Cytochemical demonstration of oxidative damage in Alzheimer's disease by immunochemical enhancement of the carbonyl reaction with 2,4- dinitrophenylhydrazine. J Histochem Cytochem 1998; 46:731-735 (Pubitemid 28272207)
40. Korolainen MA, Nyman TA, Nyyssonen P, Hartikainen ES, Pirttila T. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer's disease. Clin Chem 2007; 53:657-665 (Pubitemid 46580235)
41. Sayre LM, Zelasko DA, Harris PL, Perry G, Salomon RG, Smith MA. 4 Hydroxynonenalderived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem 1997; 68:2092-2097 (Pubitemid 27176147)
42. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid- reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 1995; 45:1594-1601
43. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid b-peptide. J Neurochem 1997; 68:255-264 (Pubitemid 26427315)
44. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging 1998; 19:33-36 (Pubitemid 28167792)
45. Arlt S, Beisiegel U, Kontush A. Lipid peroxidation in neurodegeneration: new insights into Alzheimer's disease. Curr Opin Lipidol 2002; 13:289-294 (Pubitemid 34592286)
46. Selley ML, Close DR, Stern SE. The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease. Neurobiol Aging 2002; 23:383-388 (Pubitemid 34312021)
47. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide-role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69:273-284 (Pubitemid 27274182)
48. Mattson MP, Chan SL. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 2003; 34:385-397 (Pubitemid 37021231)
49. Tamagno E, Robino G, Obbili A, Bardini P, Aragno M, Parola M, et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating Jnos and p38MAPK. Exp Neurol 2003; 180:144-155
50. Brucekeller AJ, Li YJ, Lovell MA, Kraemer PJ, Gary DS, Brown RR, et al. 4-Hydroxynonenal, a product of lipid peroxidation, damages cholinergic neurons and impairs visuospatial memory in rats. J Neuropath Exp Neur 1998; 57:257-267 (Pubitemid 28125506)
51. Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J Neurochem 1998; 71:2034-2040 (Pubitemid 28491559)
52. Collins AR, Dusinská M, Gedik CM, Stetina R. Oxidative damage to DNA: do we have a reliable biomarker? Environ Health Perspect 1996; 104:465-469
53. White AR, Barnham KJ, Bush AI. Metal homeostasis in Alzheimer's disease. Expert Rev Neurother 2006; 6:711-722
54. Nunomura A, Perry G, Pappolla MA, Wade R, Hirai K, Chiba S, et al. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neuroscience 1999; 19:1959-1964 (Pubitemid 29133374)
55. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol 2001; 60:759-767 (Pubitemid 32678256)
56. Lovell MA, Gabbita SP, Markesbery WR. Increased DNA oxidation and decreassed levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 1999; 72:771-776 (Pubitemid 29055242)
57. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36:747-751 (Pubitemid 24337634)
58. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, et al. Oxidative damage in Alzheimer's. Nature 1996; 382:120-121
59. Ortwerth BJ, Olesen PR. Ascorbic acid-induced crosslinking of lens proteins: evidence supporting a Maillard reaction. Biochim Biophys Acta 1988; 956:10-22. (Pubitemid 18214075)
60. Prabhakaram M, Ortwerth BJ. Determination of glycation crosslinking by the sugardependent incorporation of [14C]lysine into protein. Anal Biochem 1994; 216:305-312 (Pubitemid 24076012)
61. Li YM, Dickson DW. Enhanced binding of advanced glycation endproducts (age) by the apoe4 isoform links the mechanism of plaque deposition in Alzheimer's disease. Neurosci Lett 1997; 226:155-158 (Pubitemid 27201967)
62. Munch G, Cunningham AM, Riederer P, Braak E. Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease. Brain Res 1998; 796:307-310 (Pubitemid 28343263)
63. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, et al. Transition metalmediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur J Biochem 2000; 267:4171-4178 (Pubitemid 30436113)
64. González C, Farías G, Maccioni RB. Modification of tau to an Alzheimer's type protein interferes with its interaction with microtubules. Cell Mol Biol 1998; 44:1117-1127
65. Ledesma MD, Pérez M, Colaco C, Avila J. Tau glycation is involved in aggregation of the protein but not in the formation of filaments. Cell Mol Biol 1998; 44:1111-1116
66. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer's disease. Proc Natl Acad Sci USA 1994; 91:4766-4770 (Pubitemid 24177730)
67. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, et al. Glycated tau protein in Alzheimer's disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994; 91:7787-7791 (Pubitemid 24238270)
68. Colaco CA, Harrington CR. Glycation: a pathological modification in neuropathies?: a hypothesis. Neuroreport 1994; 5:859-861
69. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci 1995; 18:172-176
70. Mattson MP, Carney JW, Butterfield DA. A tombstone in Alzheimer's? Nature 1995; 373:481.
71. Blum-Degen D, Frölich L, Hoyer S, Riederer P. Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm 1995; 46:139-147
72. Hoyer S. Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 1998; 105:415-422 (Pubitemid 28365026)
73. Breteler MM, Bots ML, Ott A, Hofman A. Risk factors for vascular disease and dementia. Haemostasis 1998; 28:167-173 (Pubitemid 29309598)
74. Curb JD, Rodriguez BL, Abbott RD, Petrovitch H, Ross GW, Masaki KH, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes and glucose tolerance. Neurology 1999; 52:971-975 (Pubitemid 29161605)
75. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC, et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997; 826:422-427 (Pubitemid 27478066)
76. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53:1937-1942
77. Stewart R, Liolitsa D. Type 2 diabetes mellitus, cognitive impairment and dementia. Diabet Med 1999; 16:93-112.
78. Keller JN, Pang Z, Geddes JW, Begley JG, Germeyer A, Waeg G, et al. Impairment of glucose and glutamate transport and induction of mitochondrial oxidative stress and dysfunction in synaptosomes by amyloid beta-peptide: role of the lipid peroxidation product 4-hydroxynonenal. J Neurochem 1997; 69:273-284 (Pubitemid 27274182)
79. Luo Y, Bond JD, Ingram VM. Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases. Proc Natl Acad Sci USA 1997; 94:9705-9710 (Pubitemid 27408127)
80. Yen SH, Liu WK, Hall FL, Yan SD, Stern D, Dickson DW. Alzheimer neurofibrillary lesions: molecular nature and potential roles of different components. Neurobiol Aging 1995; 16:381-387
81. Arendt T, Hanisch F, Holzer M, Brückner MK. In vivo phosphorylation in the rat basal nucleus induces PHF-like and APP immunoreactivity. Neuroreport 1994; 5:1397-1400
82. Arendt T, Holzer M, Fruth R, Brückner MK, Gärtner U. Paired helical filament-like phosphorylation of tau, deposition of beta/A4-amyloid and memory impairment in rat induced by chronic inhibition of phosphatase 1 and 2A. Neuroscience 1995; 69:691-698
83. Janke C, Gartner U, Holzer M, Arendt T. Reversible in vivo phosphorylation of tau induced by okadaic acid and by unspecific brain lesion in rat. J Hirnforsch 1998; 39:143-153 (Pubitemid 128682841)
84. Münch G, Gerlach M, Sian J, Wong A, Riederer P. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol 1998; 44:85-88
85. Thome J, Kornhuber J, Münch G, Schinzel R, Taneli Y, Zielke B, et al. New hypothesis on etiopathogenesis of Alzheimer syndrome. Advanced glycation end products (AGEs) Nervenarzt 1996; 67:924-929
86. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382:685-691 (Pubitemid 26282167)
87. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955 (Pubitemid 32946067)
88. Münch G, Taneli Y, Schraven E, Schindler U, Schinzel R, Palm D, et al. The cognitionenhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation. J Neural Transm Park Dis Dement Sect 1994; 8:193-208.
89. Shoda H, Miyata S, Liu BF, Yamada H, Ohara T, Suzuki K, et al. Inhibitory effects of tenilsetam on the Maillard reaction. Endocrinology 1997; 138:1886-1892 (Pubitemid 27180803)
90. Staehelin HB. Micronutrients and Alzheimer's disease. Proc Nutr Soc 2005; 64:565-570
91. Ueda Y, Miyata T, Hashimoto T, Yamada H, Izuhara Y, Sakai H, et al. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia. Biochem Biophys Res Commun 1998; 245:785-790 (Pubitemid 28413995)
92. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995; 34:3702-3709
93. Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, Litchfield JE, Ahmed MU, Reddy S, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996; 11:41-47 (Pubitemid 27062910)
94. Grundman M. Vitamin E and Alzheimer's disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71:630-636
95. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal antiinflammatory drugs in Alzheimer's disease. Neurology 1995; 45:51-55
96. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, et al. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16:523-530
97. Fiebich BL, Lieb K, Kammerer N, Hull M. Synergistic inhibitory effect of ascorbic acid and acetylsalicylic acid on prostaglandin E2 release in primary rat microglia. J Neurochem 2003; 86:173-178 (Pubitemid 36753858)